EMA Makes Progress On Real-World Evidence ‘Use Cases’ With HTA Bodies & Payers

 
• By Vibha Sharma

The European Medicines Agency is looking at how it can generate real-world evidence on multiple myeloma and non-small cell lung cancer using its new DARWIN EU platform so that the outcomes can also be of use for health technology assessment bodies and payers.

Patient data
RWE can complement the evidence generated by randomized controlled clinical trials • Source: Shutterstock

More from Europe

More from Geography